Show simple item record

dc.contributor.authorKroopnick, Jeffrey M
dc.contributor.authorMartinez-Outschoorn, Ubaldo
dc.contributor.authorTuluc, Madalina
dc.contributor.authorKim, Caroline S
dc.date.accessioned2021-06-09T18:35:05Z
dc.date.available2021-06-09T18:35:05Z
dc.date.issued2021-01-19
dc.identifier.urihttp://hdl.handle.net/10713/15971
dc.description.abstractIntroduction: Hypercalcemia of malignancy (HCM) portends a very poor prognosis, and no established guidelines exist regarding its management. Most instances of HCM are due to local osteolysis or secretion of parathyroid hormone related-peptide, while less than 1% of all cases are due to ectopic secretion of parathyroid hormone. Case report: We present an unusual case of HCM due to proposed cosecretion of both parathyroid hormone and parathyroid hormone-related protein in a 36-year-old man with a poorly differentiated lung adenocarcinoma. The patient's hypercalcemia was refractory to conventional measures, including intravenous bisphosphonate therapy (zoledronic acid), and was improved with administration of denosumab. Conclusion: This is the youngest and first case of hypercalcemia of malignancy attributed to cosecretion of PTH and PTHrP from an adenocarcinoma. In refractory cases of HCM, denosumab is a potential option when other conventional measures are unsuccessful.en_US
dc.description.urihttps://doi.org/10.1016/j.aace.2021.01.003en_US
dc.language.isoenen_US
dc.publisherAmerican Association of Clinical Endocrinologistsen_US
dc.relation.ispartofAACE Clinical Case Reportsen_US
dc.subject1,25 vitamin D, 1,25-dihydroxy vitamin Den_US
dc.subjectHCM, hypercalcemia of malignancyen_US
dc.subjectHD, hospital dayen_US
dc.subjectHypercalcemia of malignancyen_US
dc.subjectPTH, parathyroid hormoneen_US
dc.subjectPTHrP, parathyroid hormone-related peptideen_US
dc.subjectZA, zoledronic aciden_US
dc.subjectcosecretion of PTH and PTHrPen_US
dc.subjectectopic PTHen_US
dc.subjecthypercalcemia of malignancyen_US
dc.titleHypercalcemia of Malignancy Attributed to Cosecretion of PTH and PTHRP in Lung Adenocarcinomaen_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.aace.2021.01.003
dc.identifier.pmid34095488
dc.source.volume7
dc.source.issue3
dc.source.beginpage200
dc.source.endpage203
dc.source.countryUnited States


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record